EN

Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth ...

BUCHLER, T., Alexandr POPRACH, Zbyněk BORTLÍČEK, Radek LAKOMÝ, Renata CHLOUPKOVÁ, Rostislav VYZULA, M. ZEMANOVA, K. KOPECKOVA, Marek SVOBODA, Ondřej SLABÝ, Igor KISS, H. STUDENTOVA, J. HORNOVA, O. FIALA, J. KOPECKY, J. FINEK, Ladislav DUŠEK a B. MELICHAR. Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer. CLINICAL GENITOURINARY CANCER, DALLAS: CIG MEDIA GROUP, LP, 2017, roč. 15, č. 6, s. "E1047"-"E1053". ISSN 1558-7673. doi:10.1016/j.clgc.2017.06.006.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer
Autoři BUCHLER, T. (203 Česká republika), Alexandr POPRACH (203 Česká republika, domácí), Zbyněk BORTLÍČEK (203 Česká republika, garant, domácí), Radek LAKOMÝ (203 Česká republika, domácí), Renata CHLOUPKOVÁ (203 Česká republika, domácí), Rostislav VYZULA (203 Česká republika, domácí), M. ZEMANOVA (203 Česká republika), K. KOPECKOVA (203 Česká republika), Marek SVOBODA (203 Česká republika, domácí), Ondřej SLABÝ (203 Česká republika, domácí), Igor KISS (203 Česká republika, domácí), H. STUDENTOVA (203 Česká republika), J. HORNOVA (203 Česká republika), O. FIALA (203 Česká republika), J. KOPECKY (203 Česká republika), J. FINEK (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí) a B. MELICHAR (203 Česká republika).
Vydání CLINICAL GENITOURINARY CANCER, DALLAS, CIG MEDIA GROUP, LP, 2017, 1558-7673.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor Oncology
Stát vydavatele Spojené státy americké
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 2.539
Kód RIV RIV/00216224:14110/17:00095683
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.clgc.2017.06.006
UT WoS 000417112200017
Klíčová slova anglicky Pazopanib; Renal cell carcinoma; Sorafenib; Sunitinib; Survival
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Soňa Böhmová, učo 232884. Změněno: 21. 3. 2018 16:23.
Anotace
Although targeted therapies are the mainstay of treatment for metastatic renal cell carcinoma there are limited data on the outcomes of patients with long-term responses. We report the outcomes of a registry-based study of patients continuously treated with first-line targeted therapy for at least 24 months. There were clinically important differences in survival between patients who achieved complete response and those with partial response or stable disease. These differences had not been described before and are important for treatment optimization of this patient subgroup. Background: Although targeted therapies with inhibitors of the vascular endothelial growth factor (VEGF) are the mainstay of treatment for metastatic renal cell carcinoma, there are limited data on the outcome of patients with long-term response to this treatment. Patients and Methods: In a retrospective, registry-based study, patients continuously treated with first-line anti-VEGF agents for at least 24 months were included. In total, 219 patients had evaluable data and were included in the outcome analysis. Results: Median progression-free survival (PFS) after initiation of first-line targeted therapy was 39.7 months (95% confidence interval [CI], 35.9-43.5 months), with 5-year PFS of 34.2% (95% CI, 27.2%-41.2%). Median overall survival (OS) reached 79.1 months (95% CI, 65.2-93.0 months) with the 5-year OS of 62.1% (95% CI, 54.5%-69.7%). In this cohort, 28, 103, and 88 patients achieved complete response (CR), partial response (PR), or stable disease (SD) as the best response, respectively. Median PFS and OS were comparable in patients with PR and SD, but significantly longer in patients with CR (log rank test P value for PFS difference <.001 and.009 for OS difference). Conclusion: There are marked differences in PFS and OS between patients who receive long-term anti-VEGF treatment, achieving CR and non-CR as the best clinical response. Patients with non-CR experienced a relatively high progression rate shortly after the landmark time point of 2 years. (C) 2017 Elsevier Inc. All rights reserved.
Návaznosti
NV15-34678A, projekt VaVNázev: Molekulární prognostické a prediktivní faktory u pacientů s metastatickým renálním karcinomem léčených tyrozinkinázovými inhibitory
VytisknoutZobrazeno: 19. 4. 2019 16:59

Další aplikace